fulvestrant has been researched along with Cancer of Liver in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Aranda, E; Chien, C; Drnevich, J; Imir, OB; Katzenellenbogen, BS; Kulkoyluoglu-Cotul, E; Liu, YJ; Madak Erdogan, Z; Mogol, AN; O'Neill, JD; Park, BH; Park, NH; Raghavendra, AS; Santaliz Casiano, A; Shapiro, DJ; Tripathy, D; Ziegler, Y; Zuo, Q | 1 |
| Cao, J; Gong, C; Hu, X; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Gibson, K; Iyer, S; Milligan, G; Mitra, D; Taylor-Stokes, G; Waller, J | 1 |
| He, M; Hu, XC; Ji, L; Jiang, YZ; Li, JJ; Shao, ZM; Wang, ZH; Zuo, WJ | 1 |
| Guo, DK; Shen, DW; Tang, L; Wang, C; Wang, CJ; Wang, J; Xu, RH; You, TG; Zhang, H | 1 |
| Bines, J; Mauriac, L; Romieu, G | 1 |
| Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J | 1 |
| Beckmann, K; Beckmann, MW; Lux, MP; Thiel, F; Wenkel, EM | 1 |
| Chen, J; Lavigne, JA; Li, Y; Trush, MA; Yager, JD | 1 |
2 trial(s) available for fulvestrant and Cancer of Liver
| Article | Year |
|---|---|
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Viscera | 2009 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2003 |
7 other study(ies) available for fulvestrant and Cancer of Liver
| Article | Year |
|---|---|
Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.
Topics: Animals; Breast Neoplasms; Diet; Female; Fulvestrant; Glucose; Humans; Hydrogels; Liver Neoplasms; Mice; Receptors, Estrogen; Tumor Microenvironment | 2022 |
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; China; Disease Progression; Duration of Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Time Factors | 2020 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Piperazines; Practice Patterns, Physicians'; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Decision-Making; Diagnosis, Differential; Disease Management; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Treatment Outcome | 2019 |
Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Estradiol; Estrogen Receptor alpha; Fulvestrant; Hep G2 Cells; Humans; In Vitro Techniques; Liver Neoplasms; Male; Middle Aged; Prolactin; Repressor Proteins; RNA, Messenger; Signal Transduction; Up-Regulation; Wnt Signaling Pathway; Young Adult | 2014 |
Fulvestrant: a further treatment option for patients with metastatic uterine cancer?
Topics: Antineoplastic Agents, Hormonal; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Receptors, Estrogen; Treatment Outcome; Urinary Bladder Neoplasms; Uterine Neoplasms | 2006 |
Increased mitochondrial superoxide production in rat liver mitochondria, rat hepatocytes, and HepG2 cells following ethinyl estradiol treatment.
Topics: Animals; Carcinoma, Hepatocellular; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cells, Cultured; Estradiol; Estradiol Congeners; Estrogen Receptor Modulators; Ethinyl Estradiol; Fulvestrant; Glutathione; Liver; Liver Neoplasms; Male; Mitochondria, Liver; Rats; Rats, Inbred F344; Superoxides; Tumor Cells, Cultured | 1999 |